Citations (54)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Ragini Vuppugalla, Yueping Zhang, Shu Chang, A. David Rodrigues & Punit H. Marathe. (2012) Impact of nonlinear midazolam pharmacokinetics on the magnitude of the midazolam-ketoconazole interaction in rats. Xenobiotica 42:11, pages 1058-1068.
Read now
Read now
N. Kanayama, C. Kanari, Y. Masuda, S. Ohmori & T. Ooie. (2007) Drug–drug interactions in the metabolism of imidafenacin: Role of the human cytochrome P450 enzymes and UDP-glucuronic acid transferases, and potential of imidafenacin to inhibit human cytochrome P450 enzymes. Xenobiotica 37:2, pages 139-154.
Read now
Read now
G. J. Pass & S. McLean. (2002) Inhibition of the microsomal metabolism of 1,8-cineole in the common brushtail possum (Trichosurus vulpecula) by terpenes and other chemicals. Xenobiotica 32:12, pages 1109-1126.
Read now
Read now
G. G. Gibson, N. J. Plant, K. E. Swales, A. Ayrton & W. El-Sankary. (2002) Receptor-dependent transcriptional activation of cytochrome P4503A genes: induction mechanisms, species differences and interindividual variation in man. Xenobiotica 32:3, pages 165-206.
Read now
Read now
Articles from other publishers (50)
HONGBING WANG & WEN XIE. 2022. Drug Metabolism Handbook. Drug Metabolism Handbook
427
464
.
Oliver Scherf-Clavel. (2022) Drug–Drug Interactions With Over-The-Counter Medicines: Mind the Unprescribed. Therapeutic Drug Monitoring 44:2, pages 253-274.
Crossref
Crossref
Anne N. Nafziger & Joseph S. BertinoJrJr. 2018. Drug Interactions in Infectious Diseases: Mechanisms and Models of Drug Interactions. Drug Interactions in Infectious Diseases: Mechanisms and Models of Drug Interactions
259
284
.
Stéphane Mouly, Célia Lloret-Linares, Pierre-Olivier Sellier, Damien Sene & J.-F. Bergmann. (2017) Is the clinical relevance of drug-food and drug-herb interactions limited to grapefruit juice and Saint-John’s Wort?. Pharmacological Research 118, pages 82-92.
Crossref
Crossref
Alexander V. LyubimovStéphane Mouly, Isabel Spriet, Joost Wauters, Pieter Annaert, Christophe Meune & Jean‐François Bergmann. 2011. Encyclopedia of Drug Metabolism and Interactions. Encyclopedia of Drug Metabolism and Interactions
1
48
.
Vaishali Sahasrabudhe, Tong Zhu, Alfin Vaz & Susanna Tse. (2015) Drug Metabolism and Drug Interactions: Potential Application to Antituberculosis Drugs. Journal of Infectious Diseases 211:suppl 3, pages S107-S114.
Crossref
Crossref
Laurent P. Rivory. 2014. Handbook of Anticancer Pharmacokinetics and Pharmacodynamics. Handbook of Anticancer Pharmacokinetics and Pharmacodynamics
351
371
.
Tonika Bohnert & Lawrence L. Gan. 2014. Handbook of Metabolic Pathways of Xenobiotics. Handbook of Metabolic Pathways of Xenobiotics
1
61
.
Lijun Zhu, Xiaoshan Yang, Juan Zhou, Lan Tang, Bijun Xia, Ming Hu, Fuyuan Zhou & Zhongqiu Liu. (2013) The exposure of highly toxic aconitine does not significantly impact the activity and expression of cytochrome P450 3A in rats determined by a novel ultra performance liquid chromatography–tandem mass spectrometric method of a specific probe buspirone. Food and Chemical Toxicology 51, pages 396-403.
Crossref
Crossref
Verònica Ventura, Josep Solà, Concepción Peraire, Françoise Brée & Rosendo Obach. (2012) In Vitro Evaluation of the Interaction Potential of Irosustat with Drug-Metabolizing Enzymes. Drug Metabolism and Disposition 40:7, pages 1268-1278.
Crossref
Crossref
Takushi Kanazu, Norihito Sato, Kyoko Kadono, Akira Touchi, Yuri Takeda, Yoshitaka Yamaguchi & Takahiko Baba. (2012) Investigation of drug-drug interaction via mechanism-based inhibition of cytochrome P450 3A by macrolides in dexamethasone-treated female rats. Biopharmaceutics & Drug Disposition 33:4, pages 195-206.
Crossref
Crossref
Sheila Annie Peters. 2012. Physiologically‐Based Pharmacokinetic (PBPK) Modeling and Simulations. Physiologically‐Based Pharmacokinetic (PBPK) Modeling and Simulations
183
207
.
T.-M. Hu & W. L. Hayton. (2011) Architecture of the drug-drug interaction network. Journal of Clinical Pharmacy and Therapeutics 36:2, pages 135-143.
Crossref
Crossref
Anne N. Nafziger, Joseph S. BertinoJr.Jr. & Joseph S. BertinoJr.Jr.. 2011. Drug Interactions in Infectious Diseases. Drug Interactions in Infectious Diseases
631
653
.
Cuyue Tang & Thomayant Prueksaritanont. (2010) Use of In Vivo Animal Models to Assess Pharmacokinetic Drug-Drug Interactions. Pharmaceutical Research 27:9, pages 1772-1787.
Crossref
Crossref
Hongbing Wang & wen xie. 2010. Pharmaceutical Sciences Encyclopedia. Pharmaceutical Sciences Encyclopedia
1
30
.
Frédéric Y. Bois. (2010) Physiologically Based Modelling and Prediction of Drug Interactions. Basic & Clinical Pharmacology & Toxicology 106:3, pages 154-161.
Crossref
Crossref
Thorsten Lehr, Alexander Staab, Dirk Trommeshauser, Hans Guenter Schaefer & Charlotte Kloft. (2010) Semi-Mechanistic Population Pharmacokinetic Drug-Drug Interaction Modelling of a Long Half-Life Substrate and Itraconazole. Clinical Pharmacokinetics 49:1, pages 53-66.
Crossref
Crossref
Thomayant Prueksaritanont. 2010. Enzyme- and Transporter-Based Drug-Drug Interactions. Enzyme- and Transporter-Based Drug-Drug Interactions
283
297
.
Xiangming Guan. 2009. Evaluation of Drug Candidates for Preclinical Development. Evaluation of Drug Candidates for Preclinical Development
109
133
.
Tonika Bohnert & Liang‐Shang Gan. 2009. Enzyme Inhibition in Drug Discovery and Development. Enzyme Inhibition in Drug Discovery and Development
91
176
.
Trevor N. Johnson, Thomas Kerbusch, Barry Jones, Geoffrey T. Tucker, Amin Rostami‐Hodjegan & Peter A. Milligan. (2009)
Assessing the efficiency of mixed effects modelling in quantifying metabolism based drug–drug interactions: using
in vitro
data as an aid to assess study power
. Pharmaceutical Statistics 8:3, pages 186-202.
Crossref
Crossref
Stéphane Mouly, Christophe Meune & Jean-François Bergmann. (2009) Mini-series: I. Basic science. Uncertainty and inaccuracy of predicting CYP-mediated in vivo drug interactions in the ICU from in vitro models: focus on CYP3A4. Intensive Care Medicine 35:3, pages 417-429.
Crossref
Crossref
Hongbing Wang & Wen Xie. 2009. Drug Metabolism Handbook. Drug Metabolism Handbook
449
478
.
Jinhan He & Wen Xie. 2009.
87
116
.
Stefanie D. Krämer & Bernard Testa. (2008) The Biochemistry of Drug Metabolism – An Introduction. Chemistry & Biodiversity 5:12, pages 2465-2578.
Crossref
Crossref
Jie Zhou, Yonggong Zhai & Wen Xie. 2008. Antitargets. Antitargets
293
316
.
Thomas Fox & Jan M. Kriegl. 2007.
63
81
.
Thomayant Prueksaritanont, Chunze Li, Cuyue Tang, Yuhsin Kuo, Kristie Strong-Basalyga & Brian Carr. (2006) Rifampin Induces the in Vitro Oxidative Metabolism, but Not the in Vivo Clearance of Diclofenac in Rhesus Monkeys. Drug Metabolism and Disposition 34:11, pages 1806-1810.
Crossref
Crossref
Bernard Testa & Stefanie D. Krämer. (2006) The Biochemistry of Drug Metabolism – An Introduction. Chemistry & Biodiversity 3:10, pages 1053-1101.
Crossref
Crossref
Thomayant Prueksaritanont, Yuhsin Kuo, Cuyue Tang, Chunze Li, Yue Qiu, Bing Lu, Kristie Strong-Basalyga, Karen Richards, Brian Carr & Jiunn H. Lin. (2006) In Vitro and in Vivo CYP3A64 Induction and Inhibition Studies in Rhesus Monkeys: A Preclinical Approach for CYP3A-Mediated Drug Interaction Studies. Drug Metabolism and Disposition 34:9, pages 1546-1555.
Crossref
Crossref
Delphine Jouin, Nadège Blanchard, Eliane Alexandre, Frédéric Delobel, Pascale David-Pierson, Thierry Lavé, Daniel Jaeck, Lysiane Richert & Philippe Coassolo. (2006) Cryopreserved human hepatocytes in suspension are a convenient high throughput tool for the prediction of metabolic clearance. European Journal of Pharmaceutics and Biopharmaceutics 63:3, pages 347-355.
Crossref
Crossref
Stuart McLean & Alan J. Duncan. (2006) Pharmacological Perspectives on the Detoxification of Plant Secondary Metabolites: Implications for Ingestive Behavior of Herbivores. Journal of Chemical Ecology 32:6, pages 1213-1228.
Crossref
Crossref
Gregor Zlokarnik, Peter D.J. Grootenhuis & John B. Watson. (2005) High throughput P450 inhibition screens in early drug discovery. Drug Discovery Today 10:21, pages 1443-1450.
Crossref
Crossref
Marcella Martignoni, Ruben de Kanter, Anna Moscone, Pietro Grossi & Mario Monshouwer. (2004) Lack of strain-related differences in drug metabolism and efflux transporter characteristics between CD-1 and athymic nude mice. Cancer Chemotherapy and Pharmacology 55:2, pages 129-135.
Crossref
Crossref
S. Polak, J. Brandys & A. Mendyk. (2005) Neural System for in silico Drug-Drug Interaction Screening. Neural System for in silico Drug-Drug Interaction Screening.
Haibiao Gong, Michael W. Sinz, Yan Feng, Taosheng Chen, Raman Venkataramanan & Wen Xie. 2005. Phase II Conjugation Enzymes and Transport Systems. Phase II Conjugation Enzymes and Transport Systems
598
618
.
Adam G. STAINESPavel SINDELAR, Michael W. H. COUGHTRIEBrian BURCHELL. (2004)
Farnesol is glucuronidated in human liver, kidney and intestine
in vitro
, and is a novel substrate for UGT2B7 and UGT1A1
. Biochemical Journal 384:3, pages 637-645.
Crossref
Crossref
D. K. Walker. (2004) The use of pharmacokinetic and pharmacodynamic data in the assessment of drug safety in early drug development. British Journal of Clinical Pharmacology 58:6, pages 601-608.
Crossref
Crossref
Stanislav Micuda, Lucie Mundlova, Eva Anzenbacherova, Pavel Anzenbacher, Jaroslav Chladek, Leos Fuksa & Jirina Martinkova. (2004) Inhibitory effects of memantine on human cytochrome P450 activities: prediction of in vivo drug interactions. European Journal of Clinical Pharmacology 60:8, pages 583-589.
Crossref
Crossref
Tommy B. Andersson, Eva Bredberg, Hans Ericsson & Helena Sjöberg. (2004) AN EVALUATION OF THE IN VITRO METABOLISM DATA FOR PREDICTING THE CLEARANCE AND DRUG-DRUG INTERACTION POTENTIAL OF CYP2C9 SUBSTRATES. Drug Metabolism and Disposition 32:7, pages 715-721.
Crossref
Crossref
Hannah M. Jones, David Hallifax & J. Brian Houston. (2004) QUANTITATIVE PREDICTION OF THE IN VIVO INHIBITION OF DIAZEPAM METABOLISM BY OMEPRAZOLE USING RAT LIVER MICROSOMES AND HEPATOCYTES. Drug Metabolism and Disposition 32:5, pages 572-580.
Crossref
Crossref
Mohamed El Mouelhi, Dan J. Worley, Barbara Kuzmak, Anthony J. Destefano & Gary A. Thompson. (2013) Influence of Azimilide on CYP2C19‐Mediated Metabolism. The Journal of Clinical Pharmacology 44:4, pages 373-378.
Crossref
Crossref
Hiroyuki YAMAZAKI, Hideki FUJINO, Mizuho KANAZAWA, Taro TAMAKI, Fumiyasu SATO, Mikio SUZUKI & Masaki KITAHARA. (2004) Pharmacological and pharmacokinetic features and clinical effects of pitavastatin (Livalo Tablet®). Folia Pharmacologica Japonica 123:5, pages 349-362.
Crossref
Crossref
Laurent P. Rivory. 2004. Handbook of Anticancer Pharmacokinetics and Pharmacodynamics. Handbook of Anticancer Pharmacokinetics and Pharmacodynamics
245
266
.
Michael W. Sinz. 2004. Applications of Pharmacokinetic Principles in Drug Development. Applications of Pharmacokinetic Principles in Drug Development
75
132
.
Pierre Kremers. (2003)
In vitro
Tests for Predicting Drug‐Drug Interactions: The Need for Validated Procedures
. Pharmacology & Toxicology 91:5, pages 209-217.
Crossref
Crossref
Carl J. Fichtenbaum & John G. Gerber. (2002) Interactions Between Antiretroviral Drugs and Drugs Used for the Therapy of the Metabolic Complications Encountered During HIV Infection. Clinical Pharmacokinetics 41:14, pages 1195-1211.
Crossref
Crossref
Takashi Matsubara. (2002) Safety Evaluation and Drug Development based on Biological Fate of Drugs —Efforts Made to Overcome Drug Interaction in Drug Development—. Drug Metabolism and Pharmacokinetics 17:5, pages 379-394.
Crossref
Crossref
Tamihide Matsunaga, Shigeru Ohmori, Mikiko Ishida, Yasuko Sakamoto, Hiromitsu Nakasa & Mitsukazu Kitada. (2002) Molecular Cloning of Monkey CYP2C43 cDNA and Expression in Yeast. Drug Metabolism and Pharmacokinetics 17:2, pages 117-124.
Crossref
Crossref